Ixazomib Citrate in Treating Patients With Chronic Graft-versus-Host Disease

PHASE2CompletedINTERVENTIONAL
Enrollment

50

Participants

Timeline

Start Date

December 8, 2015

Primary Completion Date

January 5, 2018

Study Completion Date

June 27, 2018

Conditions
Chronic Graft Versus Host Disease
Interventions
DRUG

Ixazomib Citrate

Given PO

OTHER

Laboratory Biomarker Analysis

Correlative studies

OTHER

Quality-of-Life Assessment

Ancillary studies

OTHER

Questionnaire Administration

Ancillary studies

Trial Locations (6)

27599

UNC Lineberger Comprehensive Cancer Center, Chapel Hill

33612

Moffitt Cancer Center, Tampa

44195

Cleveland Clinic Foundation, Cleveland

63110

Washington University School of Medicine, St Louis

68198

University of Nebraska Medical Center, Omaha

98109

Fred Hutch/University of Washington Cancer Consortium, Seattle

All Listed Sponsors
collaborator

National Cancer Institute (NCI)

NIH

lead

Fred Hutchinson Cancer Center

OTHER

NCT02513498 - Ixazomib Citrate in Treating Patients With Chronic Graft-versus-Host Disease | Biotech Hunter | Biotech Hunter